Federal grants to CND Life Sciences, Inc.
CND Life Sciences, Inc. in Scottsdale, Arizona received $7.9 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Extramural Research Programs in the Neurosciences and Neurological Disorders, with $5.5 million. In fiscal 2025 it was awarded $1.3 million.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$7.9 million
- Awards4
- Awarded in FY 2025$1.3 million
- Largest award$3.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 1 | $1.2 million |
| FY 2022 | 2 | $2.3 million |
| FY 2023 | 2 | $2.1 million |
| FY 2024 | 1 | $954,862 |
| FY 2025 | 1 | $1.3 million |
Programs that fund CND Life Sciences, Inc.
| Program | Awards | Amount |
|---|---|---|
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 3 | $5.5 million |
| Aging Research | 1 | $2.4 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $7.9 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Cutaneous phosphorylated alpha-synuclein for detection of prodromal synucleinopathies - project summary a group of devastating diseases, collectively termed synucleinopathies, affect over 2 million people in the U.S., carry significant morbidity, high mortality and enormous associated health care co | Extramural Research Programs in the Neurosciences and Neurological Disorders | September 12, 2022 | $3.0 million |
| A diagnostic test for dementia with lewy bodies - summary the objective of this study is to validate a diagnostic test for distinguishing two types of dementias—dementia with lewy bodies (DLB) and alzheimer’s disease (AD). Dlb is the second most common type of dementias after ad, affecting over 1.4 | Aging Research | March 9, 2022 | $2.4 million |
| Analysis of cutaneous phosphorylated alpha-synuclein to identify patients at risk of progressing from essential tremor to parkinson's disease - project summary—in this direct-to-phase II sbir, cnd life sciences proposes to 1) advance the development of a test to identify patients with essential trem | Extramural Research Programs in the Neurosciences and Neurological Disorders | August 27, 2025 | $1.3 million |
| Phs 2019-02 omnibus solicitation of the NIH, CDC, and fda for small business innovation research grant applications (parent sbir [R43/R44] clinical trial not allowed | Extramural Research Programs in the Neurosciences and Neurological Disorders | August 17, 2021 | $1.2 million |
Questions people ask
How much federal grant money does CND Life Sciences, Inc. get?
$7.9 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives CND Life Sciences, Inc. the most?
The Department of Health and Human Services, with $7.9 million in 4 awards.
What is CND Life Sciences, Inc.'s largest federal grant?
$3.0 million under Extramural Research Programs in the Neurosciences and Neurological Disorders, with its first action in the period on September 12, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund CND Life Sciences, Inc.?
Its largest are Extramural Research Programs in the Neurosciences and Neurological Disorders and Aging Research.
Other grant recipients in Scottsdale
- Salt River Pima-Maricopa Indian Community
- Mayo Clinic Arizona
- City of Scottsdale
- Maricopa County Community College District
- Vitalant
- Salt River Pima-Maricopa Indian Community
- Sequitur Health Corp.
- Spoc Proteomics Inc.
Largest federal grant recipients in Arizona · Federal grants in Arizona